Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020January 2021
News Every Day |

Gilead updates 2020 guidance to raise sales outlook, tighten and lower top end of EPS range

Gilead Sciences Inc. updated its guidance for 2020 on Monday, raising its outlook for sales to reflect sales of COVID-19 treatment remdesivir, while narrowing and lowering the top end of its per-share outlook. In a statement released ahead of a presentation at J.P. Morgan's annual healthcare conference which is being held virtually this year, the company said it now expects per-share earnings to range from a loss of 8 cents to a profit of 2 cents, compared with earlier guidance for a loss of 25 cents to a profit of 10 cents. Adjusted EPS is expected to range from $6.98 to $7.08, compared with a FactSet consensus of $6.61. The company is expecting product sales to range from $24.3 billion to $24.35 billion, up from prior guidance of $23.0 billion to $23.5 billion. Sales of remdesivir, which is sold under the brand name Veklury, are expected to range from $2.800 billion to $2.825 billion. Shares were up 0.8% premarket, but are down 3.1% in the last 12 months, while the S&P 500 has gained 17%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.





Read also

Woman desperate to look like Jac Jossa spends £60 on her coat but it makes her look like ‘Ghostbusters’ marshmallow man’

Conor McGregor in talks with Floyd Mayweather over sensational $1BILLION rematch as UFC star looks for revenge

Tim Anderson is happy to have former teammates — and opponents — come to the Chicago White Sox after an active offseason: ‘All those guys are competitive and they are definitely going to help us’




News, articles, comments, with a minute-by-minute update, now on Today24.pro



Today24.pro — latest news 24/7. You can add your news instantly now — here